Deferoxamine (DFO) is one of the most commonly used chelation treatments for transfusional hemosiderosis. Pattern dystrophies constitute a distinct entity of retinal disorders that has been occasionally identified in association with deferoxamine.
We report two cases of bilateral macular pattern dystrophy in transfusion dependent patients undergoing chronic chelation therapy with deferoxamine due to thalassemias. Our patients were evaluated with multimodal imaging and the results are presented. Both patients had normal cone and rod responses in the full-field electroretinogram and continued the prescribed chelation therapy, after hematology consult. The patients were followed up every 3 months for 2 and 4 years respectively for possible deterioration. Their best corrected visual acuity remained stable with no anatomic change on Optical Coherence Tomography findings.
Multimodal imaging of our patients allowed a better evaluation and possibly earlier detection of the DFO-related changes. Screening and close follow up of patients under chronic chelating therapy is important in order to promptly diagnose and manage possible toxicity either with discontinuation of the offending agent or dose modification.
Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, Jordan L, Lanzkron SM, Lottenberg R, Savage WJ, Tanabe PJ, Ware RE, Murad MH, Goldsmith JC, Ortiz E, Fulwood R, Horton A, John-Sowah J. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312:1033–48. CrossRefPubMed
Barteselli G, Dell'arti L, Finger RP, Charbel Issa P, Marcon A, Vezzola D, Mapelli C, Cassinerio E, Cappellini MD, Ratiglia R, Viola F. The spectrum of ocular alterations in patients with beta-thalassemia syndromes suggests a pathology similar to pseudoxanthoma elasticum. Ophthalmology. 2014;121:709–18. CrossRefPubMed
Bonkovsky HL, Davidoff A, Stark DD. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000; 343:1656. author reply 1657.
Hadziahmetovic M, Pajic M, Grieco S, Song Y, Song D, Li Y, Cwanger A, Iacovelli J, Chu S, Ying G, Connelly J, Spino M, Dunaief J. The oral Iron Chelator Deferiprone protects against retinal degeneration induced through diverse mechanisms. Transl Vis Sci Technol. 2012;1:7. CrossRefPubMedPubMedCentral
Walia HS, Yan J. Reversible retinopathy associated with oral deferasirox therapy. BMJ Case Rep. 2013; 2013. pii: bcr2013009205.
Jiang C, Hansen RM, Gee BE, Kurth SS, Fulton AB. Rod and rod mediated function in patients with beta-thalassemia major. Doc Ophthalmol. 1999;96:333–45. CrossRef
Roulez F. Retinal pigment epithelium-desferal. Bull Soc Belge Ophtalmol. 2007;304:59–66.
Genead MA, Fishman GA. Efficacy of brinzolamide ophthalmic suspension 1% for treatment of a vitelliform macular lesion in a patient with desferrioxamine retinopathy. Ophthalmic Surg Lasers Imaging 2011;42:e114–e117.Online.
- Pattern dystrophies in patients treated with deferoxamine: report of two cases and review of the literature
Constantine D. Georgakopoulos
Elli V. Kostopoulou
Olga E. Makri
- BioMed Central